Beyond Air to Participate in the 38th Annual Roth Conference in March

Core Insights - Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide to enhance patient care [4] - The company will be represented by Steve Lisi, Chairman & CEO, at the 38th Annual Roth Conference from March 22nd to 24th, 2026 [1][2] Company Overview - Beyond Air is dedicated to improving the lives of patients with respiratory illnesses, neurological disorders, and solid tumors through the use of nitric oxide [4] - The company has received FDA approval and CE Mark for its LungFit PH system, aimed at treating term and near-term neonates with hypoxic respiratory failure [4] - Beyond Air is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [4] Research and Development - Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring ultra-high concentrations of nitric oxide with a proprietary delivery system for targeting specific solid tumors in pre-clinical studies [5]